Clinical trials: Contrast Induced Nephropathy
Acute ST Segment Elevation Myocardial Infarction
Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients
Contrast induced acute kidney injury has commonly been referred to as contrast induced nephropathy (CIN) defined as an increase in serum creatinine ≥25% or ≥0.5 mg/dl from baseline within 48-72 hours with peak incidence 2-5 days…
- Trial name
- NCT04730778
- Testing
- serum creatinine and estimated glomerular filtration rate, on daily basis
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Cairo University
Acute Kidney Injury, Contrast-induced Nephropathy
Clinical Validation of the RENISCHEM L-FABP POC Assay
This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM…
- Trial name
- SAKURA-POC (NCT04864847)
- Testing
- RENISCHEM L-FABP POC Test
- Where
- 6 sites in United States
- Volunteers
- 382 people
- Sponsor
- Hikari Dx, Inc.
Radiocontrast-induced Nephropathy
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Millions of people receive radiographic contrast material for investigations like CT and coronary angiography. While considered safe in healthy patients, it can cause acute renal impairment.
- Trial name
- NCT00558142
- Testing
- Acetylcysteine, Visipaque 320
- Where
- United Kingdom
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Renal Insufficiency, Chronic, Angioplasty, Transluminal, Percutaneous Coronary
Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)
The purpose of this study is to demonstrate that Iodixanol 320 is associated with a lower incidence of contrast-induced nephropathy (CIN) when compared with hyperosmolar contrast medium Iomeprol 350 in patients with impaired…
- Conditions
- Renal Insufficiency, Chronic, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Arteriosclerosis
- Trial name
- NCT00390585
- Testing
- Iodixanol 320, Iomeprol 350
- Where
- 2 sites in Germany
- Volunteers
- 324 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Radiographic Contrast Agent Nephropathy
Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate
Contrast induced nephropathy is a rising cause of acute renal failure in all patients. A study published in JAMA 2004, show a superiority of a hydratation with sodium bicarbonate in comparison with the same volume hydratation…
- Trial name
- NCT00540904
- Testing
- sodium bicarbonate, NaCl
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Barretos Cancer Hospital
Kidney Failure, Acute, Contrast Media
Bicarbonate v Saline to Prevent Contrast Nephropathy
Slowing of kidney function occurs in a minority of people given dye during angiography. The purpose of this study is to compare two different types of fluid given into a vein to reduce the risk of kidney injury: salt in water or…
- Trial name
- NCT00384995
- Testing
- 0.9% (154 mEq/L) IV Sodium Chloride, 1/6 M (166 mEq/L) IV Sodium Bicarbonate
- Where
- 5 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Italian Society of Nephrology
Contrast-induced Acute Kidney Injury, Acute Coronary Syndromes
DyeVert System and Contrast-induced Acute Kidney Injury
The aim of the REnal Insufficiency Following Contrast MEDIA Administration TriaL IV (REMEDIAL IV) is to test whether the use of the DyeVert system is effective in reducing CI-AKI rate in ACS patients undergoing urgent/immediate…
- Trial name
- REMEDIALIV (NCT04714736)
- Testing
- Coronary angiography using DyeVert system, Coronary angiography using conventional manual injection syringe.
- Where
- 2 sites in Italy
- Volunteers
- 522 people
- Sponsor
- Clinica Mediterranea
Impaired Renal Function
Longterm Follow-up After Remote Ischemic Preconditioning for Prevention of Contrast-induced Nephropathy
Remote ischemic preconditioning reduces the incidence of contrast-induced acute kidney injury in patients undergoing elective coronary angiography.
- Trial name
- RenProLong (NCT01760031)
- Testing
- Ischemic preconditioning
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- University of Cologne
Contrast-induced Acute Kidney Injury
Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury
This a prospective, double-blind, sham-controlled, randomized clinical trial to study the effects of remote ischemic preconditioning on acute kidney injury, vascular and renal biomarkers in patients with non-ST elevation…
- Trial name
- BRICK (NCT03236441)
- Testing
- RIPC
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Oladipupo Olafiranye, MD, MS
Kidney Failure
PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography
The contrast induced kidney toxicity has been known to affect the mortality and morbidity in the patients undergoing coronary angiography. But the mechanism and therapeutic strategy for it is not well known.
- Trial name
- NCT00259441
- Testing
- Simvastatin
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Seoul National University Hospital
Contrast-Induced Nephropathy, Acute Myocardial Infarction
Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction
Patients with acute myocardial infarction undergoing primary angioplasty are at high risk for renal injury due to the toxic effect of contrast agents.
- Trial name
- NCT00237614
- Testing
- intravenous and oral N-acetylcysteine
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Milan
Myocardial Infarction, Death
Prognostic Impact of Organ Damage in STEMI Patients
Besides contrast-induced acute kidney injury (CI-AKI), adscititious vital organ damage such as hypoxic liver injury (HLI) may affect the survival in patients with ST-elevation myocardial infarction (STEMI).
- Conditions
- Myocardial Infarction, Death, Acute Kidney Injury, Hepatic Insufficiency
- Trial name
- NCT02800421
- Volunteers
- 668 people
- Sponsor
- Inha University Hospital
Contrast-induced Nephropathy
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.
- Trial name
- NCT06429345
- Testing
- Coenzyme Q10 100 Milligrams Oral Capsule
- Where
- 2 sites in Egypt
- Volunteers
- 250 people
- Sponsor
- Ain Shams University
Chronic Kidney Disease Stage 2, Radiographic Contrast Agent Nephropathy
N-Acetyl Cystein and Contrast Nephropathy
There are many controversies about the role of N-Acetyl Cystein in preventing of contrast nephropathy. These contradictory results may be due to different criteria for patients' selection, different end points, different type and…
- Trial name
- NCT01820195
- Testing
- Oral N-Acetyl Cystein, IV N-Acetyl Cystein
- Where
- Iran
- Volunteers
- 549 people
- Sponsor
- Imam Khomeini Hospital
Acute Kidney Injury, Acute Renal Failure
Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)
This is a prospective, observational, multi-center study with consecutive enrollment. Up to 500 patients will be enrolled. All (consecutive) adult patients in whom one or more components of the Benephit Infusion System are…
- Conditions
- Acute Kidney Injury, Acute Renal Failure, Renal Failure Chronic Contrast Induced, Chronic Kidney Disease
- Trial name
- PROVIDE (NCT01064895)
- Testing
- Benephit catheter for Targeted Renal Therapy
- Where
- 15 sites in United States
- Sponsor
- Angiodynamics, Inc.
KIDNEY FAILURE, ACUTE
Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration
The purpose of this study is to compare the efficacy of oral versus intravenous hydration in the prevention of the contrast-induced nephropathy.
- Trial name
- NIC (NCT00908843)
- Testing
- Intravenous hydration with bicarbonate, Oral hydration with Sodium solution
- Where
- Spain
- Volunteers
- 167 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Left Cardiac Catheterization, Percutaneous Coronary Intervention
Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
Left heart catheterization and percutaneous coronary intervention (PCI) has become a useful tool in interventional cardiology, in which iodinated contrast media is used.
- Conditions
- Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury, Sodium-glucose Co-transporter 2 Inhibitors
- Trial name
- NCT04806633
- Testing
- Dapagliflozin 5mg
- Where
- 2 sites in Greece
- Volunteers
- 1,722 people
- Sponsor
- G.Gennimatas General Hospital
Pentoxifylline, Contrast Induced Nephropathy
Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit
The aim of this study is to evaluate the effect of pentoxifylline for control of contrast induced nephropathy in chronic kidney diseased patients in intensive care unit.
- Conditions
- Pentoxifylline, Contrast Induced Nephropathy, Chronic Kidney Disease, Intensive Care Unit
- Trial name
- NCT07561801
- Testing
- Pentoxifylline, Normal saline
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Contrast Medium-induced Nephropathy
Prevention of Contrast Renal Injury With Different Hydration Strategies
Using a randomized controlled trial design, two hydration protocols for the prevention of contrast medium-induced nephropathy will be tested.
- Trial name
- POSEIDON (NCT01218828)
- Testing
- LVEDP -Based hydration strategy, Standard hydration
- Where
- United States
- Volunteers
- 396 people
- Sponsor
- Kaiser Permanente
Contrast Induced Kidney Injury.
Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease
Patients with Stage 3B, 4,or 5 Chronic Kidney Disease who are to undergo an angiography procedure with contrast agent will be asked if they are willing to join the trial.
- Trial name
- BOSS (NCT00930436)
- Testing
- sodium bicarbonate
- Where
- 17 sites in United States
- Volunteers
- 391 people
- Sponsor
- MD Scientific